Oct 7 (Reuters) - Briacell Therapeutics Corp BCT.V :
* BRIACELL DOSES FIRST PATIENT IN PHASE I/IIA STUDY EVALUATING BRIA-IMT™ IN COMBINATION WITH INCMGA00012 AND EPACADOSTAT IN PATIENTS WITH ADVANCED BREAST CANCER
* BRIACELL THERAPEUTICS CORP - EXPECT TO REPORT PRELIMINARY SAFETY DATA IN 4Q 2019
* BRIACELL - INITIATED DOSING IN A PHASE I/IIA CLINICAL STUDY OF ITS LEAD PRODUCT CANDIDATE, BRIA-IMT, IN COMBINATION WITH INCYTE'S INCMGA00012